Alpha 2.0
Login Register
» Authors » Valentina Foschi

Valentina Foschi

Explore the profile of Valentina Foschi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 235
Followers 0
Related Specialties
Rheumatology
Allergy & Immunology
General Medicine
Top 10 Co-Authors
Florenzo Iannone
Marcello Govoni
Fausto Salaffi
Julia Martinez-Barrio
Roberto Bortolotti
Kostantinos Triantafyllias
Christof Specker
Tamara Ziglioli
Mauro Galeazzi
Javier Bachiller Corral
Published In
J Rheumatol
Clin Rev Allergy Immunol
Autoimmun Rev
Clin Cancer Res
Medicine (Baltimore)
Affiliations
Soon will be listed here.
Recent Articles
1.
Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity
Stratigou V, Doyle A, Carlucci F, Stephens L, Foschi V, Castelli M, et al.
Rheumatology (Oxford) . 2017 Apr; 56(7):1206-1216. PMID: 28387859
Objectives: The aim was to investigate whether the signalling lymphocyte activation molecule (SLAM) signalling pathways contribute to LN and whether SLAM receptors could be valuable biomarkers of disease activity. Methods:...
2.
Merkel Cell Carcinomas Arising in Autoimmune Disease Affected Patients Treated with Biologic Drugs, Including Anti-TNF
Rotondo J, Bononi I, Puozzo A, Govoni M, Foschi V, Lanza G, et al.
Clin Cancer Res . 2017 Feb; 23(14):3929-3934. PMID: 28174236
The purpose of this investigation was to characterize Merkel cell carcinomas (MCC) arisen in patients affected by autoimmune diseases and treated with biologic drugs. Serum samples from patients with MCC...
3.
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group
Cavagna L, Nuno L, Scire C, Govoni M, Lopez Longo F, Franceschini F, et al.
Clin Rev Allergy Immunol . 2016 Jan; 52(1):71-80. PMID: 26782036
Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD), an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). Recently, we organized...
4.
Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study
Cavagna L, Nuno L, Scire C, Govoni M, Lopez Longo F, Franceschini F, et al.
Medicine (Baltimore) . 2015 Aug; 94(32):e1144. PMID: 26266346
Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). These manifestations...
5.
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry
Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli E, et al.
Autoimmun Rev . 2012 Jul; 12(2):225-9. PMID: 22796281
Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. Methods: The study involved...
6.
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors
Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, et al.
J Rheumatol . 2012 Apr; 39(6):1179-84. PMID: 22467933
Objective: To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry....